## **Product** Data Sheet

## HPK1-IN-4

Cat. No.:HY-138569CAS No.:2739844-28-9Molecular Formula: $C_{23}H_{26}N_6O_3$ Molecular Weight:434.49Target:MAP4K

Pathway: MAPK/ERK Pathway

Storage: Powder -20°C 3 years

4°C 2 years

In solvent -80°C 6 months

-20°C 1 month

## **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 100 mg/mL (230.15 mM; ultrasonic and adjust pH to 4 with HCl)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.3015 mL	11.5077 mL	23.0155 mL
	5 mM	0.4603 mL	2.3015 mL	4.6031 mL
	10 mM	0.2302 mL	1.1508 mL	2.3015 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE- $\beta$ -CD in saline) Solubility: 2.08 mg/mL (4.79 mM); Suspended solution; Need ultrasonic
- 2. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 0.83 mg/mL (1.91 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 0.83 mg/mL (1.91 mM); Clear solution

## **BIOLOGICAL ACTIVITY**

**Description** HPK1-IN-4 (comp 22) is a HPK1 (MAPK41) inhibitor (IC<sub>50</sub> of 0.061 nM) as preclinical immunoresearch tool compound<sup>[1]</sup>.

 $\label{eq:control_solution} \mbox{IC}_{\bf 50} \mbox{ \& Target} \qquad \qquad \mbox{IC}{\bf 50}{\rm : 0.061 \ nM \ (HPK1)}^{[1]}.$ 

**REFERENCES** 

1]. Brandon A Vara, et al. Disco 9;12(4):653-661.	very of Diaminopyrimidine Car	boxamide HPK1 Inhibitors as Pre	clinical Immunotherapy Tool Compounds	s. ACS Med Chem Lett. 2021 Mar
	Tel: 609-228-6898	Fax: 609-228-5909	cal applications. For research use on E-mail: tech@MedChemExpress.co	
		eer Park Dr, Suite Q, Monmout		***

Page 2 of 2 www.MedChemExpress.com